NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Bamboo Therapeutics, Inc., a recently formed biotechnology company focused on advancing therapies for rare pediatric diseases of the central and neuromuscular systems, and CureDuchenne, a nonprofit organization dedicated to funding research and improving patient care for Duchenne muscular dystrophy, will host a webinar “Bamboo Therapeutics – Developing a novel gene therapy for patients with Duchenne Muscular Dystrophy” on Monday, June 13 at 3 p.m. ET/noon PT.
Speakers include:
- Sharon Hesterlee, Ph.D., EVP Patient Advocacy and Public Affairs, Bamboo Therapeutics
- Jude Samulski, Ph.D., Scientific Founder, Bamboo Therapeutics, and former Director of the Gene Therapy Center at the University of North Carolina
- Jak Knowles, MD, Vice President Medical and Scientific Affairs, CureDuchenne, and Managing Director CureDuchenne Ventures
- Debra Miller, Founder and CEO, CureDuchenne
During the webinar, Dr. Hesterlee and Dr. Samulski will discuss the basics of gene therapy and a description of Bamboo’s approach to developing a treatment for Duchenne muscular dystrophy; a gene therapy utilizing a disabled virus to deliver a small, highly optimized version of the dystrophin gene systemically to skeletal and cardiac muscle. The gene therapy, originally called BMB-D001, has already shown positive effects in Duchenne animal models, improving life span as well as skeletal and cardiac muscle function in both mice and rats. Life extension and maintenance of ambulation up to eight years post-treatment resulted from long-term dystrophin production in a canine Duchenne animal model.
CureDuchenne Ventures LLC, a venture philanthropy organization that funds research to find a cure for Duchenne muscular dystrophy, provided funding for Bamboo Therapeutics to help advance their gene therapy treatment for Duchenne. This financial support will enable critical pre-IND enabling studies to accelerate advancement of the therapy to patient clinical trials.
Duchenne is a progressive muscle-wasting disease affecting more than 300,000 boys worldwide. Boys with Duchenne are usually diagnosed by the age of 5, lose the ability to walk by age 12 and most don’t survive their mid-20s. There is currently no approved treatment for Duchenne.
To register for the webinar on June 13, click here. The call in number is 844-337-8088 and the conference ID number is 22853541.
About Bamboo Therapeutics, Inc.
Bamboo represents a community of researchers, clinicians, parents, regulatory scientists, and business professionals committed to providing hope to patients suffering from debilitating disease. Bamboo is focused on some of the most devastating neurological and neuromuscular diseases that affect children. Our lead therapeutic is a gene therapy product for the treatment of Duchenne muscular dystrophy. Bamboo's therapeutics are derived from an exclusive rAAV platform technology, and are manufactured using a proprietary scaled up process at an established GMP vector core facility recently purchased by the company.
About CureDuchenne
CureDuchenne was founded in 2003 with a focus on saving the lives of those with Duchenne muscular dystrophy. Affecting 1 in 3,500 boys, Duchenne is the most common and lethal form of muscular dystrophy. CureDuchenne has garnered international attention for its innovative model of funding the most impactful research through venture philanthropy and providing superior patient care through CureDuchenne Cares. For additional information, please visit CureDuchenne.org and follow us on Facebook, Twitter and YouTube.
